Nasdaq · CIK 0001750149
IKT Inhibikase Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Aug 28, 2025. Close $1.97 on Oct 9, 2026, +40% from the 52-week low and -22% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
IKTOct 9, 2026 · close 1.97
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Inhibikase Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | Roberto Bellini director buy | $2.0M 1,460,000 shares | - | - | |
| 56Moderate | Amit Munshi director buy | $500k 365,000 shares | - | - | |
| 50Moderate | Arvind Kush director buy | $199k 145,000 shares | - | - |
Transactions
The last 91 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 21, 2025 | Amit Munshi director | AGrant or award Common Stock | +57,265 | $0.00 | $0 | 57,265 | Aug 28, 2025 |
| Jun 30, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivative | +108,176 | $0.00 | $0 | 108,176 | Jul 2, 2025 |
| Jun 30, 2025 | Roberto Bellini director | AGrant or award Stock Option (Right to Buy)derivative | +108,176 | $0.00 | $0 | 108,176 | Jul 2, 2025 |
| Jun 30, 2025 | David Canner director | AGrant or award Stock Option (Right to Buy)derivative | +108,176 | $0.00 | $0 | 108,176 | Jul 2, 2025 |
| Jun 30, 2025 | Arvind Kush director | AGrant or award Stock Option (Right to Buy)derivative | +108,176 | $0.00 | $0 | 108,176 | Jul 2, 2025 |
| Jun 30, 2025 | Amit Munshi director | AGrant or award Stock Option (Right to Buy)derivative | +108,176 | $0.00 | $0 | 108,176 | Jul 2, 2025 |
| Jun 30, 2025 | Vincent Aurentz director | AGrant or award Stock Option (Right to Buy)derivative | +108,176 | $0.00 | $0 | 108,176 | Jul 2, 2025 |
| Feb 21, 2025 | Mark T Iwicki Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +602,346 | $0.00 | $0 | 602,346 | Jul 2, 2025 |
| Feb 21, 2025 | Christopher Cabell President & Head of R&D | AGrant or award Stock Option (Right to Buy)derivative | +1,100,705 | $0.00 | $0 | 1,100,705 | Jul 2, 2025 |
| Feb 21, 2025 | Vincent Aurentz director | AGrant or award Stock Option (Right to Buy)derivative | +134,427 | $0.00 | $0 | 134,427 | Jul 2, 2025 |
| Apr 14, 2025 | David McIntyre Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,775,539 | $0.00 | $0 | 1,775,539 | Apr 16, 2025 |
| Feb 21, 2025 | Mark T Iwicki Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +602,346 | $0.00 | $0 | 602,346 | Feb 25, 2025 |
| Feb 21, 2025 | Christopher Cabell President & Head of R&D | AGrant or award Stock Option (Right to Buy)derivative | +1,100,705 | $0.00 | $0 | 1,100,705 | Feb 25, 2025 |
| Feb 21, 2025 | Vincent Aurentz director | AGrant or award Stock Option (Right to Buy)derivative | +134,427 | $0.00 | $0 | 134,427 | Feb 25, 2025 |
| Feb 14, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivative | +39,620 | $0.00 | $0 | 39,620 | Feb 19, 2025 |
| Feb 14, 2025 | Mark T Iwicki Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +4,373,857 | $0.00 | $0 | 4,373,857 | Feb 19, 2025 |
| Feb 14, 2025 | Arvind Kush director | AGrant or award Stock Option (Right to Buy)derivative | +56,600 | $0.00 | $0 | 56,600 | Feb 19, 2025 |
| Feb 14, 2025 | Amit Munshi director | AGrant or award Stock Option (Right to Buy)derivative | +56,600 | $0.00 | $0 | 56,600 | Feb 19, 2025 |
| Feb 14, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +22,640 | $0.00 | $0 | 22,640 | Feb 19, 2025 |
| Feb 14, 2025 | David Canner director | AGrant or award Stock Option (Right to Buy)derivative | +22,640 | $0.00 | $0 | 22,640 | Feb 19, 2025 |
| Feb 14, 2025 | Roberto Bellini director | AGrant or award Stock Option (Right to Buy)derivative | +73,580 | $0.00 | $0 | 73,580 | Feb 19, 2025 |
| Feb 14, 2025 | David Canner director | AGrant or award Stock Option (Right to Buy)derivative | +116,585 | $0.00 | $0 | 116,585 | Feb 19, 2025 |
| Feb 14, 2025 | Roberto Bellini director | AGrant or award Stock Option (Right to Buy)derivative | +116,585 | $0.00 | $0 | 116,585 | Feb 19, 2025 |
| Feb 14, 2025 | Amit Munshi director | AGrant or award Stock Option (Right to Buy)derivative | +116,585 | $0.00 | $0 | 116,585 | Feb 19, 2025 |
| Feb 14, 2025 | Arvind Kush director | AGrant or award Stock Option (Right to Buy)derivative | +116,585 | $0.00 | $0 | 116,585 | Feb 19, 2025 |
| Feb 17, 2025 | Mark T Iwicki Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,794,291 | $0.00 | $0 | 1,794,291 | Feb 19, 2025 |
| Jan 21, 2025 | Dennis N Berman director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | -21,854 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,854 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Garth Lees-Rolfe Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,834 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | Garth Lees-Rolfe Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +5,834 | $0.00 | $0 | 5,834 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | +21,854 | $0.00 | $0 | 21,854 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +21,854 | $0.00 | $0 | 21,854 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Garth Lees-Rolfe Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -90,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,138 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,138 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +1,138 | $0.00 | $0 | 1,138 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivative | +1,138 | $0.00 | $0 | 1,138 | Jan 22, 2025 |
| Jan 21, 2025 | Garth Lees-Rolfe Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | -3,780 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,780 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +3,780 | $0.00 | $0 | 3,780 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | +3,780 | $0.00 | $0 | 3,780 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,667 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | -6,667 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +6,667 | $0.00 | $0 | 6,667 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | +6,667 | $0.00 | $0 | 6,667 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,667 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | -6,667 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +6,667 | $0.00 | $0 | 6,667 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | +6,667 | $0.00 | $0 | 6,667 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,667 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | -30,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Molino Ventures, LLC | +30,000 | $0.00 | $0 | 30,000 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +16,667 | $0.00 | $0 | 16,667 | Jan 22, 2025 |
| Jan 21, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,834 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +20,834 | $0.00 | $0 | 20,834 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jan 22, 2025 |
| Jan 3, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivative | +344,452 | $0.00 | $0 | 344,452 | Jan 7, 2025 |
| Jan 3, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +5,315,056 | $0.00 | $0 | 5,315,056 | Jan 7, 2025 |
| Jan 3, 2025 | Garth Lees-Rolfe Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +470,861 | $0.00 | $0 | 470,861 | Jan 7, 2025 |
| Jan 3, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +344,452 | $0.00 | $0 | 344,452 | Jan 7, 2025 |
| Jan 3, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +172,191 | $0.00 | $0 | 172,191 | Jan 7, 2025 |
| Jan 3, 2025 | Garth Lees-Rolfe Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +235,383 | $0.00 | $0 | 235,383 | Jan 7, 2025 |
| Jan 3, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivative | +172,191 | $0.00 | $0 | 172,191 | Jan 7, 2025 |
| Jan 3, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +2,207,671 | $0.00 | $0 | 2,207,671 | Jan 7, 2025 |
| Jan 3, 2025 | Roy Lester Freeman director | AGrant or award Stock Option (Right to Buy)derivative | +316,647 | $0.00 | $0 | 316,647 | Jan 7, 2025 |
| Jan 3, 2025 | Dennis N Berman director | AGrant or award Stock Option (Right to Buy)derivative | +316,647 | $0.00 | $0 | 316,647 | Jan 7, 2025 |
| Jan 3, 2025 | Garth Lees-Rolfe Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +432,853 | $0.00 | $0 | 432,853 | Jan 7, 2025 |
| Jan 3, 2025 | Milton H. Werner President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +4,059,744 | $0.00 | $0 | 4,059,744 | Jan 7, 2025 |
| Oct 21, 2024 | Roberto Bellini director | POpen-market purchase Common Stockindirect: See footnote | +1,460,000 | $1.37 | $2.0M | 1,460,000 | Oct 23, 2024 |
| Oct 21, 2024 | David Canner director | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Oct 23, 2024 |
| Oct 21, 2024 | Amit Munshi director | POpen-market purchase Common Stockindirect: By Amit Munshi Revocable Trust | +365,000 | $1.37 | $500k | 365,000 | Oct 23, 2024 |
| Oct 21, 2024 | Arvind Kush director | POpen-market purchase Common Stock | +145,000 | $1.37 | $199k | 145,000 | Oct 23, 2024 |
| Oct 21, 2024 | Roberto Bellini director | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Oct 23, 2024 |
| Oct 21, 2024 | Amit Munshi director | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Oct 23, 2024 |
| Oct 21, 2024 | Arvind Kush director | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Oct 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Vincent Aurentzdirector
- Dennis N Bermandirector
- Roberto Bellinidirector
- Christopher CabellPresident & Head of R&D
- David Cannerdirector
- Roy Lester Freemandirector
- Mark T IwickiChief Executive Officer
- Arvind Kushdirector
- Garth Lees-RolfeChief Financial Officer
- David McIntyreChief Financial Officer
- Amit Munshidirector
- Milton H. WernerPresident and CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.